Osteoporosis Treatment Guidelines for Elderly Patients

Initial Assessment and Risk Stratification

The American College of Physicians recommends assessing fracture risk based on bone mineral density (BMD) T-score, history of fragility fractures, FRAX score, age, sex, body weight, parental history of hip fracture, and glucocorticoid use 1, 2, 3
A BMD T-score ≤-2.5 indicates osteoporosis and warrants treatment, according to the American College of Physicians 1, 3
A history of fragility fractures, particularly vertebral or hip fractures, is a significant risk factor for osteoporosis, as stated by the American College of Physicians 1, 2
A FRAX score with a 10-year risk ≥20% for major osteoporotic fracture or ≥3% for hip fracture indicates high fracture risk, according to the American College of Physicians 3, 4

The American College of Physicians recommends a calcium intake of 1,000-1,200 mg/day from diet and supplements 2, 3, 5
The American College of Physicians suggests a vitamin D intake of 600-800 IU/day, targeting a serum level ≥20-30 ng/mL 2, 3, 5
Weight-bearing and resistance training exercises, such as squats, push-ups, and heel raises, are recommended by the American College of Physicians 2, 6
Smoking cessation and limiting alcohol to 1-2 drinks/day are advised by the American College of Physicians 2, 6

The American College of Physicians strongly recommends oral bisphosphonates (alendronate, risedronate, or zoledronic acid) as first-line therapy for patients ≥65 years with T-score ≤-2.5 or high fracture risk 1, 2
Alendronate (10 mg daily or 70 mg weekly) is a recommended treatment option, according to the American Academy of Family Physicians 3
Risedronate (5 mg daily, 35 mg weekly, or 150 mg monthly) is another recommended treatment option, as stated by the American Academy of Family Physicians 3
Denosumab (60 mg subcutaneously every 6 months) is recommended for patients who are contraindicated or intolerant to oral bisphosphonates, according to the American College of Physicians 1, 2

The American College of Physicians recommends reassessing fracture risk after 5 years of continuous bisphosphonate therapy 2, 5
A "drug holiday" (temporary discontinuation) may be considered if no new fractures occur during treatment, T-score improves to >-2.5, or no very high-risk features are present, as stated by the American College of Physicians 2, 5
Continuing bisphosphonates beyond 5 years is recommended if there is a history of vertebral fracture, T-score remains ≤-2.5, or ongoing high fracture risk, according to the American College of Physicians 2, 5

The American College of Physicians recommends heightened attention to drug interactions, polypharmacy effects, renal function, and comorbidities that may contraindicate specific agents in patients >65 years 2, 5, 7
The American College of Rheumatology suggests considering renal function (adjusting or avoiding bisphosphonates if CrCl <35 mL/min) in elderly patients 7